Bitcoin is trading near $79,700, facing resistance around $81,259 after a strong 25% gain in August driven by $3.52 billion inflows into U.S. spot Bitcoin ETFs. The price could test $83,000 if it breaks above resistance but may fall to $76,206 or deeper support between $72,000 and $74,000 if rejected. Recent U.S. jobs data increased expectations for a Federal Reserve rate hike in September, adding macroeconomic uncertainty. Meanwhile, U.S. Treasury bond buybacks may improve market liquidity, indirectly supporting risk assets like Bitcoin.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
